Cargando…

Selecting Reliable mRNA Expression Measurements Across Platforms Improves Downstream Analysis

With increasing use of publicly available gene expression data sets, the quality of the expression data is a critical issue for downstream analysis, gene signature development, and cross-validation of data sets. Thus, identifying reliable expression measurements by leveraging multiple mRNA expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Pan, Diao, Lixia, Shen, Li, Li, Lerong, Heymach, John Victor, Girard, Luc, Minna, John D., Coombes, Kevin R., Byers, Lauren Averett, Wang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863871/ https://www.ncbi.nlm.nih.gov/pubmed/27199546 http://dx.doi.org/10.4137/CIN.S38590

Ejemplares similares

Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer
por: Gomez, Daniel Richard, et al.
Publicado: (2018)

Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus
por: James, Michael A., et al.
Publicado: (2012)

Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial–mesenchymal transition
por: Lin, Steven H, et al.
Publicado: (2014)

Identification and Characterization of a Suite of Tumor Targeting Peptides for Non-Small Cell Lung Cancer
por: McGuire, Michael J., et al.
Publicado: (2014)

Blasted Cell Line Names
por: Wang, Jing, et al.
Publicado: (2010)

eIF2β, a subunit of translation‐initiation factor EIF2, is a potential therapeutic target for non‐small cell lung cancer
por: Tanaka, Ichidai, et al.
Publicado: (2018)

Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer
por: Kakumu, Tomohiko, et al.
Publicado: (2017)

Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations
por: Peng, Shaohua, et al.
Publicado: (2015)

Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters
por: He, Yong, et al.
Publicado: (2012)

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
por: Stewart, C. Allison, et al.
Publicado: (2017)

Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers
por: Cardnell, Robert J., et al.
Publicado: (2019)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
por: Cardnell, Robert J., et al.
Publicado: (2016)

The Epithelial Sodium Channel (αENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors
por: He, Min, et al.
Publicado: (2018)

D-Dimer Varies Widely Across Instrument Platforms and is Not a Reliable Indicator of Periprosthetic Joint Infections
por: Pearson, Lauren N., et al.
Publicado: (2020)

ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology
por: Stewart, C. Allison, et al.
Publicado: (2021)

Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology
por: Stewart, C. Allison, et al.
Publicado: (2021)

Reproducibility of SELDI Spectra Across Time and Laboratories
por: Diao, Lixia, et al.
Publicado: (2011)

piNET: a versatile web platform for downstream analysis and visualization of proteomics data
por: Shamsaei, Behrouz, et al.
Publicado: (2020)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer
por: Massarelli, Erminia, et al.
Publicado: (2019)

Reliability of genomic variants across different next-generation sequencing platforms and bioinformatic processing pipelines
por: Weißbach, Stephan, et al.
Publicado: (2021)

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
por: Pietanza, M. Catherine, et al.
Publicado: (2018)

Molecular differences across invasive lung adenocarcinoma morphological subgroups
por: Ci, Bo, et al.
Publicado: (2020)

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies
por: Cardnell, Robert J., et al.
Publicado: (2017)

Effect of mRNA Delivery Modality and Formulation on Cutaneous mRNA Distribution and Downstream eGFP Expression
por: Darade, Aditya R., et al.
Publicado: (2022)

Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis
por: Cai, Songhua, et al.
Publicado: (2023)

Impact of RNA-seq data analysis algorithms on gene expression estimation and downstream prediction
por: Tong, Li, et al.
Publicado: (2020)

The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers
por: Kundu, Samrat T., et al.
Publicado: (2015)

Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations
por: Wang, Yuehong, et al.
Publicado: (2016)

Downstream Signalling from Molecular Hydrogen
por: Hancock, John T., et al.
Publicado: (2021)

A high throughput platform for stem cell-niche co-cultures and downstream gene expression analysis
por: Gracz, Adam D, et al.
Publicado: (2015)

mRNA Vaccine Platform: mRNA Production and Delivery
por: Litvinova, V. R., et al.
Publicado: (2023)

Assessing the clinical utility of cancer genomic and proteomic data across tumor types
por: Yuan, Yuan, et al.
Publicado: (2014)

EBP1: A crucial growth regulator downstream of receptor kinases across kingdoms
por: Stegmann, Martin
Publicado: (2018)

Effector differentiation downstream of lineage commitment in ILC1 is driven by Hobit across tissues
por: Friedrich, Christin, et al.
Publicado: (2021)

A Multimodal Protein Representation Framework for Quantifying Transferability Across Biochemical Downstream Tasks
por: Hu, Fan, et al.
Publicado: (2023)

Comparative mRNA booster effectiveness against death or hospitalization with COVID-19 pneumonia across at-risk US Veteran populations
por: Kelly, J. Daniel, et al.
Publicado: (2023)

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
por: Chen, Runzhe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_phb97i7r8bmkqqj9s9nmnjo497